Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, double-blind, randomized, active-controlled, two-armed, multicenter, efficacy and safety assessment (ACTAMESA) of org 5222 and olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder

Next Previous
X
Search
Trial Profile

A phase III, double-blind, randomized, active-controlled, two-armed, multicenter, efficacy and safety assessment (ACTAMESA) of org 5222 and olanzapine in the treatment of patients with schizophrenia or schizoaffective disorder

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 19 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Asenapine (Primary) ; Olanzapine
  • Indications Schizoaffective disorder; Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Acronyms ACTAMESA
  • Sponsors Merck Sharp & Dohme; Organon

    • Most Recent Events

    • 04 Mar 2010 Results published in Pharmacopsychiatry.
    • 06 Oct 2009 Schering-Plough added instead of Organon as Organon was taken over by Schering-Plough.
    • 06 Oct 2009 Schering-Plough added instead of Organon as Organon was taken over by Schering-Plough.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top